Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Endogenous E2 on SSI and GH Rebound
NCT02026973Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Mar 2014
- Primary completion
- Nov 2015
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of anastrozole and fulvestrant (4 arms), sponsored by Mayo Clinic. Primary endpoint: The summed mass of GH over 10 hours. Started Mar 2014; status: completed.
02
Drugs
anastrozolefulvestrant
Beyond the preview
Go deeper on NCT02026973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02026973.